Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study
F Bandello, G Staurenghi, F Ricci, E Midena… - British Journal of …, 2020 - bjo.bmj.com
Background To evaluate the safety and tolerability of ranibizumab 0.5 mg in patients with
uni/bilateral neovascular age-related macular degeneration (nAMD) and best-corrected …
uni/bilateral neovascular age-related macular degeneration (nAMD) and best-corrected …
[HTML][HTML] OLIMPIC: a 12-month study on the criteria driving retreatment with ranibizumab in patients with visual impairment due to myopic choroidal neovascularization
Purpose To evaluate criteria driving retreatment with ranibizumab in Italian patients with
myopic choroidal neovascularization (mCNV). Methods OLIMPIC was a 12-month, phase …
myopic choroidal neovascularization (mCNV). Methods OLIMPIC was a 12-month, phase …